Business
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"- AEOL 10150 Treatment Once Per Day for 60 Days Beginning 24 Hours Post-Exposure Reduced Mortality by 50 Percent- AEOL 10150 Is The Only Drug in Advanced Development by The US Government to Address the Delayed Effects of Radiation- Stockpiled Therapies Such as Neupogen®, Neulasta® And Leukine® Enhance Short Term Survival, But Also Increase the Need for and Value of Treatments to Reduce Suffering and Mortality Expected from Delayed Effects in Acute Survivors- Data Presented at The American College of Clinical Pharmacology Annual Meeting in San DiegoMISSION VIEJO, CA / ACCESSWIRE / September 26, 2017 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today presentation of pharmacometric-based analysis confirming the optimal dosing schedule for AEOL 10150 in the treatment of the pulmonary effects of acute radiation syndrome (\"Lung ARS\"). The analysis, performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD and Hechuan Wang, MS with the Center for Translational Medicine at the University of Maryland School of Pharmacy and funded by Aeolus' Lung ARS development contract with the Biomedical Advanced Research and Development Authority (\"BARDA\") confirmed the statistical significance of the improvement in survival and underlying pathophysiology seen after treatment with AEOL 10150 in NHP efficacy studies conducted by and previously reported by Thomas MacVittie, PhD at the University of Maryland School of Medicine (\"UMSOM\"). Dr. Gobburu's analysis of data from NHP and mouse efficacy studies, performed under the BARDA contract, concluded that administration of AEOL 10150 for 60 days beginning 24 hours after exposure to lethal radiation provided the best survival benefit and that this level of efficacy demonstrated in an \"adequate and well designed\" study would likely produce a dose modification factor supporting approval under the Animal Rule. The results of the analysis, titled AEOL 10150 Improves 180-day Survival of Lethally Irradiated Rhesus Macaques, were presented at the American College of Clinical Pharmacology annual meeting in San Diego.\"Our pharmocometric-based modeling results show that AEOL 10150 treatment for 60 days at a dose of 5 mg/kg/day provides statistically significant survival be...